Phathom Pharmaceuticals
Phathom Pharmaceuticals' revenue rose 216.9% to $175 million in fiscal 2025. Its operating margin was −91.4%, up from −502.2% a year earlier. Free cash flow was −$167 million. The diluted share count rose 15.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Phathom Pharmaceuticals does
Phathom Pharmaceuticals is a drug company that sells medicines for stomach and digestive diseases. Its products are VOQUEZNA tablets and two co-packaged kits, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK. All three contain vonoprazan, a pill that blocks acid production in the stomach. Phathom says VOQUEZNA is the only drug of its type, a potassium-competitive acid blocker, approved for sale in the United States.
VOQUEZNA is approved for erosive and non-erosive gastroesophageal reflux disease (GERD, or chronic acid reflux) and, with antibiotics, for H. pylori stomach infection. The two kits treat H. pylori infection. All of its revenue comes from these three products, sold in the United States through its own sales force aimed at gastroenterologists and other high-prescribing providers. It says its products have commercial insurance coverage for over 80% of U.S. commercial lives. It competes with older acid-reducing drugs called proton pump inhibitors.
Phathom licensed U.S., European and Canadian rights to vonoprazan from Takeda in 2019. It began selling the products in November 2023. It started a Phase 2 trial in eosinophilic esophagitis in late 2025. As of December 31, 2025, it had 371 full-time employees.
Its biggest risks, as it describes them
- It depends entirely on the success of its three VOQUEZNA products, especially for GERD.
- It has lost money since it began and may need more financing, while its royalty and loan agreements limit its cash.
- It has limited experience selling medicines, and insurers and government programs may not cover or pay for them well.
- It relies on third parties to manufacture its products and run its clinical trials.
- It could lose the rights to vonoprazan if its license from Takeda ends.
Income statement
Phathom Pharmaceuticals lost money in fiscal 2025: a net loss of $221 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 183 | 155 | 381 | 297 | 130 |
| Debt incl. finance leases | 90 | 95 | 138 | 201 | 209 |
| Net debt (negative means net cash) | −94 | −60 | −244 | −96 | 79 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.2x | — | — | — | — |
| Interest coverage | −19.9x | −6.3x | −4.0x | −3.9x | −2.4x |
| Current ratio | 9.9x | 6.1x | 10.2x | 4.2x | 1.7x |
| Quick ratio | 9.9x | 6.1x | 10.2x | 4.2x | 1.7x |
Cash flow
Projections
Project Phathom Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Phathom Pharmaceuticals reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 4 of 9 | 4 of 9 |
| Rule of 40 | — | 7,518.4% | 121.6% |
| Altman Z'' | −4.50 | −11.48 | −21.03 |
| Accruals ratio | −22.1% | −17.1% | −17.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 8 | 4 of 9 | 4 of 9 |
Compare
Put Phathom Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals | FY25 | 216.9% | −91.4% | −95.4% | — | — | 4 | |
| Syndax Pharmaceuticals | FY25 | 627.8% | −158.4% | −187.5% | — | — | — | Compare |
| Kamada | FY25 | 12.1% | 14.5% | 8.7% | — | — | — | Compare |
| Glass House Brands | FY25 | −9.4% | −9.1% | −8.6% | −10.0% | — | 3 | Compare |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | 0 | 1 | 55 | 175 |
| Revenue growth | — | — | — | — | — | — | 8,001.5% | 216.9% |
| Gross profit | — | — | — | — | 0 | 0 | 47 | 152 |
| Research and development | 0 | 20 | 98 | 72 | 71 | 50 | 34 | 33 |
| Operating income | −1 | −106 | −126 | −135 | −172 | −167 | −278 | −160 |
| Net income | −1 | −255 | −129 | −144 | −198 | −202 | −334 | −221 |
| Diluted EPS (US$) | −0.21 | −22.45 | −3.88 | −3.89 | −5.05 | −3.93 | −5.29 | −3.03 |
| Diluted shares (millions) | 6 | 11 | 33 | 37 | 39 | 51 | 63 | 73 |
| Cash flow | ||||||||
| Cash from operations | −1 | −36 | −70 | −148 | −146 | −138 | −267 | −167 |
| Capital expenditure | — | 0 | 1 | 0 | 1 | 2 | 0 | 0 |
| Free cash flow | — | −37 | −71 | −149 | −148 | −139 | −267 | −167 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 6 | 17 | 24 | 45 | 24 | 29 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 1 | 244 | 288 | 183 | 155 | 381 | 297 | 130 |
| Debt incl. finance leases | — | 23 | 47 | 90 | 95 | 138 | 201 | 209 |
| Total assets | 1 | 257 | 295 | 189 | 165 | 414 | 378 | 259 |
| Total liabilities | 2 | 29 | 101 | 117 | 240 | 487 | 632 | 697 |
| Shareholders' equity | −1 | 228 | 194 | 72 | −75 | −73 | −254 | −438 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | 75.5% | 85.6% | 87.1% |
| Operating margin | — | — | — | — | — | −24,532.5% | −502.2% | −91.4% |
| Net margin | — | — | — | — | — | −29,558.9% | −605.1% | −126.3% |
| Free cash flow margin | — | — | — | — | — | −20,412.6% | −483.1% | −95.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | 7,518.4% | 121.6% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −225.1% | −61.1% | −108.0% | — | — | — | — |
| Return on assets | — | −197.7% | −46.7% | −59.4% | −111.6% | −69.7% | −84.4% | −69.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |